Simon Estcourt
Simon joins TMC from Abacus Medicine Pharma Services, where he was Managing Director, successfully growing the company by partnering with developers of innovative therapies and tailoring bespoke commercialisation solutions. After graduating with a degree in Business and Politics from Aston University, Simon began his career in the pharmaceutical services industry working in business development for Quintiles/Innovex for a number of years before joining Idis, gaining extensive global experience in corporate development, strategic planning, executive management and leadership at director and senior vice president roles, graduating to president status leading the managed access programs division. After joining the Clinigen Group, he continued working at C-suite level, prior to his last role at Abacus before joining TMC.
Simon brings a wealth of senior leadership experience in the pharma services space and will support TMC with its continued global expansion.
Simon joined TMC in May 2024.
Carol Woodward
With a degree from the University of East Anglia, Carol joined the pharmaceutical industry, working at Lederle Laboratories, Schering AG before joining Shire Pharmaceuticals. At Shire she contributed to the drug development process as a Program Leader. During this time Carol also completed an MSc in Clinical Research at the University of Wales.
Carol has extensive experience across many therapeutic areas, particularly oncology and all development phases. She has held roles in both Pharma companies and Clinical Research Organisations, including senior positions such as the Global Therapeutic Head of Haematology/Oncology at PPD and Vice President Development Innovations and European Operations at Sarah Cannon.
Carol joined TMC in March 2020.
Joe Lopez
Joe joins TMC from Sondrel Holdings plc, where he was Chief Financial Officer and successfully took the company public in 2022. He has been a chartered accountant for over 25 years and Chief Financial Officer for 15 years, primarily focused on international businesses.
Qualifying originally with Grant Thornton, he has worked in a variety of directorship roles in the UK and Europe, ranging from start-ups to corporate multi nationals, bringing with him extensive executive management and growth management experience of delivering sustainable value in international environments that will ably support TMC’s continued global expansion.
Joe joined TMC in May 2024.
John Lagus
With a graduate degree in statistics from Iowa State University, John joined the pharmaceutical industry working at 3M Pharmaceuticals before he joined Orphan Medical where he oversaw the development and FDA approval of ANTIZOL. John transitioned to the pharma services sector with various leadership roles in business development, corporate development, marketing, and general operational management at Idis, Clinigen, Tanner Pharma Group, and Bluestem Pharma Consulting.
John has extensive experience in the pharmaceutical industry that can be leveraged to support TMC with its global growth.
John joined TMC in July 2025.
Catherine Moncad
With a Joint Honours degree in Biochemistry and Biology, Catherine entered the pharmaceutical industry taking a Data Management role at PAREXEL before moving to Regulatory Affairs, via R&D, at Reckitt.
Catherine has held regulatory roles at Smith & Nephew and PRA, gaining extensive experience in OTCs, generics, devices, prescription pharmaceuticals and wide clinical trial experience.
Since joining TMC, she heads the Regulatory Services team that supports clients with all stages of drug development from early non-clinical, through to clinical, to licence applications and even post-approval support.
Catherine joined TMC in March 2017.
Dr Victoria Datsenko
Victoria has over 20 years of clinical development experience within global clinical research, including both project management and line management.
A medically qualified doctor, her extensive experience covers all clinical trial phases across a broad range of indications and therapies with particular expertise in oncology and cell therapy.
Victoria’s Clinical Services team comprises experienced and highly capable Project Directors, Project Managers, CRAs and CTAs allowing her direct oversight and governance of all aspects of our clinical projects.
Victoria joined TMC in 2022.
Nichola Worship
With a First Class BSc in Food Science & Physiology (Kings College, London), Nichola began her career in the pharmaceutical industry, working primarily in clinical research. She later moved to the pharma services sector, working for leading CROs in a number of areas including project, resource and risk management and training. As a senior project director Nichola has led the global oversight of clinical trials portfolios, ensuring projects were managed within time, quality, and budget guidelines. Her responsibilities covered trial execution strategy, developing and maintaining good client relationships, achieving repeat business within the neuroscience, immunology, and infectious disease therapeutic areas.
Nichola brings extensive experience in senior leadership account director roles, and her expertise in bridging the gap between the client and their pharma services partnership is paramount to building on the global success of TMC.
Nichola joined TMC in January 2025.
Marcelo Vaz
Medically qualified in 1992 and with an early career specialising in Pulmonary academia and clinical practice, Marcelo moved to the pharmaceutical industry in 2007, initially as a Senior Clinical Research Physician before becoming a Medical Director at a large CRO.
Marcelo developed clinical research expertise across the range of respiratory diseases, including COPD, Asthma, Lung Cancer, Cystic Fibrosis, Respiratory infections, Sepsis, mechanical ventilation, ARDS and SIRS.
Other areas of clinical research experience include CV, TGI, rheumatology, woman’s health, oncology, ENT, CNS, DM. His rare diseases expertise includes supporting strategic creation of drug development plans, protocol concepts, and moving from classic to adaptive study designs.
Marcelo joined TMC in 2022.
Lucy Fulford-Smith
Lucy is an experienced clinician, having qualified as a doctor in the UK in 2013. She worked in both medical and surgical specialities, with an interest in paediatric surgery. Alongside her hospital practice in the NHS, she was regularly engaged in clinical and academic research, focusing on public health, patient engagement and advocacy and the training of allied healthcare professionals.
Since becoming a Pharmaceutical Physician in 2020, Lucy has worked in early clinical development, pharmacovigilance and medical information. She has experience working at multiple stages of the development of gene and cell therapies and has particular interest in treatments for rare diseases, oncology and paediatric indications.
As Head of PV, Lucy leads a growing team of pharmacovigilance specialists delivering clinical trial and post-marketing PV expertise. In her role as Medical Director, Lucy supports all aspects of the medical services scope of work, including clinical trials, licensing applications and post-marketings activities.
Lucy joined TMC in 2022.
Claire Willson
With a 1st Class Degree in Biology with Oceanography, Claire entered the pharmaceutical industry in 2003 via Clinical Operations at PRA Health Services, before moving to Quality Assurance in 2012.
Claire has held QA roles at CRO and Sponsor organisations providing a broad foundation of experience across the many challenges faced within the pharmaceutical industry. Therapeutic experience includes Respiratory (Pneumonia), Oncology (Breast & Pancreatic) & Neurology (Complex Partial Epilepsy & Multiple Sclerosis).
Since joining TMC, Claire has headed up QA, providing Quality Oversight, QMS Management, Project Management, Training, Risk Management and Consultancy across multiple GxP areas, supporting internal and external customers while leading a diverse team of QA professionals.
Claire brings a wealth of Clinical Operations, QA, training, CRO/Sponsor and GxP experience in pharma services, well equipped to support TMC and our Clients in the dynamic research and commercial quality environments.
Claire joined TMC in July 2022.